MedTrace Logo

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

NCT02025712 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2014-01-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether exemestane plus everolimus are effective in the treatment of patients who have achieved disease stabilization after induction chemotherapy for hormone-receptor positive metastatic breast cancer.

Conditions

  • Hormone Receptor Positive Malignant Neoplasm of Breast

Interventions

DRUG

Exemestane

Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.

DRUG

Everolimus

Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.

Sponsors & Collaborators

  • Organisation for Oncology and Translational Research

    lead OTHER

Principal Investigators

  • Louis Chow · Organisation for Oncology and Translational Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2016-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02025712 on ClinicalTrials.gov